Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Ewing sarcoma (ES) family of tumors includes bone and soft tissue tumors that are often characterized by a specific translocation between chromosome 11 and 22, resulting in the EWS-FLI1 fusion gene. With the advent of multi-modality treatment including cytotoxic chemotherapy, surgery, and radiation...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00537/full |
| _version_ | 1818532446669373440 |
|---|---|
| author | Dana L. Casey Tsung-Yi Lin Nai-Kong V. Cheung |
| author_facet | Dana L. Casey Tsung-Yi Lin Nai-Kong V. Cheung |
| author_sort | Dana L. Casey |
| collection | DOAJ |
| description | Ewing sarcoma (ES) family of tumors includes bone and soft tissue tumors that are often characterized by a specific translocation between chromosome 11 and 22, resulting in the EWS-FLI1 fusion gene. With the advent of multi-modality treatment including cytotoxic chemotherapy, surgery, and radiation therapy, the prognosis for patients with ES has substantially improved. However, a therapeutic plateau is now reached for both localized and metastatic disease over the last two decades. Burdened by the toxicity limits associated with the current frontline systemic therapy, there is an urgent need for novel targeted therapeutic strategies. In this review, we discuss the current treatment paradigm of ES, and explore preclinical evidence and emerging treatments directed at tumor signaling pathways and immune targets. |
| first_indexed | 2024-12-11T17:45:38Z |
| format | Article |
| id | doaj.art-76c1017463b54d41a7fdad914380c28c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T17:45:38Z |
| publishDate | 2019-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-76c1017463b54d41a7fdad914380c28c2022-12-22T00:56:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-06-01910.3389/fonc.2019.00537454940Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing SarcomaDana L. Casey0Tsung-Yi Lin1Nai-Kong V. Cheung2Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesEwing sarcoma (ES) family of tumors includes bone and soft tissue tumors that are often characterized by a specific translocation between chromosome 11 and 22, resulting in the EWS-FLI1 fusion gene. With the advent of multi-modality treatment including cytotoxic chemotherapy, surgery, and radiation therapy, the prognosis for patients with ES has substantially improved. However, a therapeutic plateau is now reached for both localized and metastatic disease over the last two decades. Burdened by the toxicity limits associated with the current frontline systemic therapy, there is an urgent need for novel targeted therapeutic strategies. In this review, we discuss the current treatment paradigm of ES, and explore preclinical evidence and emerging treatments directed at tumor signaling pathways and immune targets.https://www.frontiersin.org/article/10.3389/fonc.2019.00537/fullEwing sarcomaantibodiesimmunotherapytargeted therapypediatric sarcomas |
| spellingShingle | Dana L. Casey Tsung-Yi Lin Nai-Kong V. Cheung Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers in Oncology Ewing sarcoma antibodies immunotherapy targeted therapy pediatric sarcomas |
| title | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| title_full | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| title_fullStr | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| title_full_unstemmed | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| title_short | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| title_sort | exploiting signaling pathways and immune targets beyond the standard of care for ewing sarcoma |
| topic | Ewing sarcoma antibodies immunotherapy targeted therapy pediatric sarcomas |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00537/full |
| work_keys_str_mv | AT danalcasey exploitingsignalingpathwaysandimmunetargetsbeyondthestandardofcareforewingsarcoma AT tsungyilin exploitingsignalingpathwaysandimmunetargetsbeyondthestandardofcareforewingsarcoma AT naikongvcheung exploitingsignalingpathwaysandimmunetargetsbeyondthestandardofcareforewingsarcoma |